Evaluation of Anticancer Therapy‐Related Tumor Flare Reaction: Insights From Food and Drug Administration's Adverse Event Reporting System Dataset
Cancer Medicine · 2026-03 · 15 (3)
DOI: 10.1002/cam4.71660 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 09.03.2026. Verfasst von Wei Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Beijing Anzhen Hospital, Capital Medical University, Beijing, P. R. China. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, Antineoplastic Agents, Neoplasms, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Anzhen Hospital Science and Technology Development Funding, Beijing Anzhen Hospital High-Level Research Funding, Beijing Bethune Charitable Foundation.
Abstract (Originalsprache)
Aim
Tumor flare reaction (TFR) is characterized by an increase in tumor size during immunotherapy, often resembling disease progression. This study explores the relationship between anti‐tumor drugs and tumor flare reaction (TFR) through the FAERS database to assist clinicians in better patient management.
Methods
We analyzed the FAERS database to identify TFR cases reported from Q1 2004 to Q3 2024. For signal detection, we employed disproportionality analysis with four algorithms—reported odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and empirical Bayes geometric mean (EBGM). These algorithms assessed statistical correlations between anticancer drugs and TFR, based on a 2 × 2 contingency table framework.
Results
From Q1 2004 to Q3 2024, 566 TFR cases were recorded in the FAERS database. The incidence of TFR peaked in 2023, with the highest increase in cases from 2021 to 2022, at 4.9%. A total of 28 anticancer drugs were identified as strongly associated with TFR, of which only 4 are explicitly listed in the medication instructions as having TFR‐related adverse reactions. Lenalidomide was the most frequent drug causing TFR, accounting for 38% of all TFR reports.
Conclusions
Our findings highlight the key associations between treatment drugs and TFR, particularly targeted therapies such as Rituximab, which are not explicitly marked for this side effect in the FAERS database. The study emphasizes the need for clinicians to closely monitor TFR in patients receiving certain cancer treatments and improve therapeutic strategies to mitigate TFR risks, ensuring safer cancer treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Beijing Anzhen Hospital, Capital Medical University, Beijing, P. R. China.
- Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, Shanxi, P. R. China.
ORCID-Profile: Ning Zhang
Förderung
- Beijing Anzhen Hospital Science and Technology Development Funding
- Beijing Anzhen Hospital High-Level Research Funding
- Beijing Bethune Charitable Foundation
- Beijing Hospitals Authority Youth Programme
- Beijing Anzhen Hospital High-Level Research Special Program (Incubation Program)
Zitieren
APA
Wang, W., Cui, J., Bo, Y., Wang, Y., Sun, Z., Guan, X., Hong, B., & Zhang, N. (2026). Evaluation of Anticancer Therapy‐Related Tumor Flare Reaction: Insights From Food and Drug Administration's Adverse Event Reporting System Dataset. Cancer Medicine, 15(3). https://doi.org/10.1002/cam4.71660
Vancouver
Wang W, Cui J, Bo Y, Wang Y, Sun Z, Guan X, et al. Evaluation of Anticancer Therapy‐Related Tumor Flare Reaction: Insights From Food and Drug Administration's Adverse Event Reporting System Dataset. Cancer Medicine. 2026;15(3). doi:10.1002/cam4.71660
BibTeX
@article{Wang2026,
author = {Wang, Wei and Cui, Jiayuan and Bo, Yuxuan and Wang, Yuxuan and Sun, Zhipeng and Guan, Xin and Hong, Baoan and Zhang, Ning},
title = {Evaluation of Anticancer Therapy‐Related Tumor Flare Reaction: Insights From Food and Drug Administration's Adverse Event Reporting System Dataset},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {3},
doi = {10.1002/cam4.71660}
}
EUVIMED